Eric Shaff, Seres Therapeutics CEO

FDA sets Seres on the pri­or­i­ty re­view path for its mi­cro­bio­me C. dif­fi­cile drug, set­ting up April de­ci­sion

Though sev­er­al com­pa­nies have been look­ing at new drugs and can­di­dates to go af­ter C. dif­fi­cile, one biotech is at the FDA’s doorstep.

Seres Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.